WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2017062888) ANTI-LAG3 ANTIBODIES AND USES THEREOF
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2017/062888    International Application No.:    PCT/US2016/056156
Publication Date: 13.04.2017 International Filing Date: 07.10.2016
IPC:
C07K 16/28 (2006.01), A61P 35/00 (2006.01), A61P 37/00 (2006.01), A61K 39/00 (2006.01)
Applicants: REGENERON PHARMACEUTICALS, INC. [US/US]; 777 Old Saw Mill River Road Tarrytown, New York 10591-6707 (US)
Inventors: ULLMAN, Erica; (US).
HERMANN, Aynur; (US).
IOFFE, Ella; (US).
BUROVA, Elena; (US).
THURSTON, Gavin; (US)
Agent: CROWLEY-WEBER, Cara L.; (US).
PRENDERGAST, Paul J.; (US).
WU, Rita S.; (US)
Priority Data:
62/239,524 09.10.2015 US
62/257,791 20.11.2015 US
62/315,119 30.03.2016 US
62/359,921 08.07.2016 US
62/365,006 21.07.2016 US
Title (EN) ANTI-LAG3 ANTIBODIES AND USES THEREOF
(FR) ANTICORPS ANTI-LAG3 ET LEURS UTILISATIONS
Abstract: front page image
(EN)The present invention provides antibodies that bind to the T cell co-inhibitor lymphocyte activation gene 3 (LAG3) protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that specifically bind to LAG3. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing LAG3 activity, thus providing a means of treating a disease or disorder such as cancer or viral infection.
(FR)La présente invention concerne des anticorps qui se lient à la protéine du gène d'activation des lymphocytes 3 (LAG3) co-inhibitrice des cellules T, et des procédés d'utilisation. Dans divers modes de réalisation de l'invention, les anticorps sont des anticorps entièrement humains qui se lient à LAG3. Dans certains modes de réalisation, les anticorps de l'invention sont utiles pour inhiber ou neutraliser l'activité de LAG3, en donnant ainsi un moyen de traitement d'une maladie ou d'un trouble tel qu'un cancer ou une infection virale.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)